Showing results (191-200 of 295) with videos related to

Sort By:
Pageof 30
Nature Communications|June 4, 2026
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapyMitchell J Elliott, Jesús Fuentes-Antrás, Sasha C Main, et al.
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
The Journal of Urology|February 24, 2018
Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell TumorRicardo Leão, Ton van Agthoven, Arnaldo Figueiredo, et al.
JCO Clinical Cancer Informatics|February 22, 2022
A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative ApproachJessica A Lavery, Eva M Lepisto, Samantha Brown, et al.
Breast Cancer Research and Treatment|August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancerVandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumorsPhilippe L Bedard, Josep Tabernero, Filip Janku, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2009
Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonistsShilan Liu, Yinhui Liu, Hongmei Wang, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell TumorsJeremy Lewin, Paul Dufort, Jaydeep Halankar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast CancerMaura N Dickler, Cristina Saura, Donald A Richards, et al.
Pageof 30